Hypertension
📧 Sign up to get email alerts when something new happens for Hypertension.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2021-09-30Clinical Trial Update: REducing Blood Pressure Variability in Essential Hypertension With RAmipril vErsus Nifedipine GITS Trial [Phase 4]
A Phase 4 trial comparing ramipril versus nifedipine GITS in reducing blood pressure variability in essential hypertension has completed.
-
CLINICAL_TRIALS trial_result · 2021-09-29Clinical Trial Update: Sacubitril/Valsartan Versus Valsartan for Hypertensive Patients With Acute Myocardial Infarction [Phase 4]
Phase 4 trial comparing Sacubitril/Valsartan to Valsartan in hypertensive patients with acute myocardial infarction.
-
CLINICAL_TRIALS trial_result · 2021-09-24Clinical Trial Update: Comparison of Blood Pressure Control Achieved in Antihypertensive or Generic Drugs in Moderate to Severe Hypertensive Patients [Phase 4]
Phase 4 trial comparing blood pressure control achieved by antihypertensive or generic drugs in adults with moderate to severe hypertension;…
-
EMA withdrawal · 2021-09-17EMA Withdrawn: Telmisartan Teva (telmisartan) — Teva B.V.
Telmisartan Teva has been withdrawn from the European market.
-
CLINICAL_TRIALS trial_result · 2021-09-16Clinical Trial Update: Pharmacogenetic Prediction of Metoprolol Effectiveness [NA]
A terminated clinical trial investigated pharmacogenetic prediction of metoprolol effectiveness in hypertension, with results posted in 2021…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2021-09-16Clinical Trial Update: Monitoring Movement and Health Study
Completed clinical trial update for a study on movement and health in pregnancy-related obesity (with hypertension considerations), results …
-
FDA approval · 2021-09-15FDA Approved: IRBESARTAN — Supplemental Application (Solco Healthcare U.S., LLC)
FDA approved a supplemental application for IRBESARTAN from Solco Healthcare U.S., LLC.
-
FDA label_change · 2021-09-15FDA Approved: METOPROLOL — Supplemental Application (Fresenius Kabi USA, LLC)
FDA approved a supplemental application for metoprolol tartrate products from Fresenius Kabi USA, LLC.
-
FDA approval · 2021-09-14FDA Approved: IRBESARTAN — Supplemental Application (Lupin Pharmaceuticals, Inc.)
The FDA approved Lupin Pharmaceuticals' supplemental application for IRBESARTAN, a generic angiotensin II receptor blocker.
-
FDA approval · 2021-09-13FDA Approved: KATERZIA — Supplemental Application (Azurity Pharmaceuticals, Inc.)
FDA approved a supplemental application for KATERZIA (amlodipine) from Azurity Pharmaceuticals, Inc., expanding the approved labeling/formul…
-
FDA label_change · 2021-09-10FDA Approved: AVALIDE — Supplemental Application (Sanofi-Aventis U.S. LLC)
FDA approved a supplemental application for AVALIDE (irbesartan/hydrochlorothiazide) submitted by Sanofi-Aventis U.S. LLC.
-
FDA label_change · 2021-09-10FDA Approved: AVAPRO — Supplemental Application (Sanofi-Aventis U.S. LLC)
The FDA approved a supplemental labeling change for AVAPRO (irbesartan) filed by Sanofi-Aventis U.S. LLC.
-
FDA approval · 2021-09-01FDA Approved: IRBESARTAN — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for IRBESARTAN from Aurobindo Pharma Limited under ANDA 203081.
-
CLINICAL_TRIALS trial_result · 2021-09-01Clinical Trial Update: The Precision Hypertension Care Study [Phase 4]
Phase 4 clinical trial update for the Precision Hypertension Care Study addressing hypertension, with the study status marked as completed.
-
CLINICAL_TRIALS trial_result · 2021-08-30Clinical Trial Update: Clinical Calibration & Validation of a Next-Generation Blood Pressure Monitor for Patient Management
Clinical trial update detailing calibration and validation of a next-generation blood pressure monitor for patient management. Study complet…
-
FDA approval · 2021-08-26FDA Approved: IRBESARTAN — Supplemental Application (Unichem Pharmaceuticals (USA), Inc.)
The FDA approved a supplemental application for IRBESARTAN filed by Unichem Pharmaceuticals (USA), Inc., effectively updating the existing A…
-
CLINICAL_TRIALS trial_result · 2021-08-24Clinical Trial Update: Comparison of Three Combination Therapies in Lowering Blood Pressure in Black Africans [Phase 4]
Phase 4 clinical trial comparing three combination therapies for lowering blood pressure in hypertensive Black African patients has complete…
-
FDA approval · 2021-08-20FDA Approved: METOLAZONE — Original Application (Advagen Pharma Limited)
FDA approved Advagen Pharma Limited's Original Application for METOLAZONE, granting approval of a generic diuretic.
-
FDA approval · 2021-08-18FDA Approved: LABETALOL HYDROCHLORIDE — Original Application (Advagen Pharma Ltd)
The FDA approved Labetalol Hydrochloride as a generic drug under an Original Application by Advagen Pharma Ltd.
-
FDA approval · 2021-08-17FDA Approved: LISINOPRIL — Supplemental Application (Camber Pharmaceuticals, Inc.)
FDA approved a supplemental application for lisinopril from Camber Pharmaceuticals, Inc., for the generic product.
-
CLINICAL_TRIALS trial_result · 2021-08-17Clinical Trial Update: Amlodipine And Olmesartan Medoxomil In Hypertensive Filipino Patients
Clinical trial update on amlodipine and olmesartan medoxomil in hypertensive Filipino patients; study terminated with posted results.
-
FDA approval · 2021-08-10FDA Approved: ENALAPRIL MALEATE ORAL SOLUTION — Original Application (Bionpharma Inc.)
FDA approved ENALAPRIL MALEATE ORAL SOLUTION from Bionpharma Inc. under Original Application ANDA212408.
-
FDA approval · 2021-08-05FDA Approved: ENALAPRIL MALEATE — Supplemental Application (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.)
FDA approved a supplemental application for enalaprilate maleate from Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc., effecti…
-
CLINICAL_TRIALS trial_result · 2021-07-28Clinical Trial Update: Olmesartan/HCTZ 40/12.5 mg Combination Therapy Versus Olmesartan Medoxomil 40 mg Monotherapy in Essential Hypertension [Phase 3]
Phase 3 trial comparing olmesartan/HCTZ 40/12.5 mg combination therapy to olmesartan monotherapy in essential hypertension has completed wit…
-
CLINICAL_TRIALS trial_result · 2021-07-28Clinical Trial Update: Clinical Trial to Evaluate the Efficacy and Safety of CKD-386 [Phase 3]
Phase 3 clinical trial evaluating CKD-386 for efficacy and safety in patients with dyslipidemia and hypertension has completed.